Drugs / Thyrotropin Releasing Hormone (TRH)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04868045 | Apr 2021 → Feb 2023 | thyroid cancer | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thyrotropin Releasing Hormone (TRH) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04868045 ↗ |
| Known as | TRH | “Drug: Thyrotropin Releasing Hormone (TRH)” NCT04868045 ↗ |
| Route | Intravenous | “TRH administration will be given as a 200-mcg single IV bolus on Day 1 and Day 5.” NCT04868045 ↗ |